Tag: Pakistan

SAN JOSE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced that Zoom and Five9 have mutually terminated the merger agreement executed by the parties on July 16, 2021.

At Five9’s special meeting of stockholders held on September 30, 2021, Five9 did not obtain the requisite stockholder support for the merger agreement. As a result, Zoom and Five9 each had the ability to terminate the merger agreement.

“While we were excited about the benefits this transaction would bring to both Zoom and Five9 stakeholders, including the long-term potential for both sets of shareholders, financial discipline is foundational to our strategy,” said Eric S. Yuan, Chief Executive Officer and Founder of Zoom. “The contact center market remains a strategic priority for Zoom, and we are confident in our ability to capture its growth potential. At Zoomtopia, we announced the Zoom Video Engagement Center, our cloud-based contact center solution, which will launch in early 2022. Video Engagement Center will be a flexible, easy-to-use solution that connects businesses and their customers. We are building this new solution with the same scalability and trusted architecture that has made Zoom the platform of choice for businesses around the world. We also plan to maintain our valued existing contact center partnerships with companies like Five9, Genesys, NICE inContact, Talkdesk, and Twilio. We remain focused on driving long-term value creation for Zoom shareholders and delivering happiness to our customers through our broad-based communications platform including unified communications, developer, and events solutions.”

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ: ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

Forward-Looking Statements
This press release contains express and implied “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Zoom’s strategic priorities, market opportunity, product launches, the expected benefits of new products, growth strategy, partnerships and expected benefits from the same, and business aspirations to support organizations and people on multiple fronts as they look to reimagine work, communications and collaboration. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements, including: declines in new customers and hosts, renewals or upgrades, difficulties in evaluating our prospects and future results of operations given our limited operating history, competition from other providers of communications platforms, continued uncertainty regarding the extent and duration of the impact of COVID-19 and the responses of government and private industry thereto, including the potential effect on our user growth rate once the impact of the COVID-19 pandemic tapers, particularly as a vaccine becomes widely available, and users return to work or school or are otherwise no longer subject to shelter-in-place mandates, as well as the impact of COVID-19 on the overall economic environment, any or all of which will have an impact on demand for remote work solutions for businesses as well as overall distributed, face-to-face interactions and collaboration using Zoom, delays or outages in services from our co-located data centers, and failures in internet infrastructure or interference with broadband access which could cause current or potential users to believe that our systems are unreliable. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in our most recent filings with the Securities and Exchange Commission (the “SEC”), including our quarterly report on Form 10-Q for the fiscal quarter ended July 31, 2021. Forward-looking statements speak only as of the date the statements are made and are based on information available to Zoom at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Zoom assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Press Relations
Colleen Rodriguez
Global Public Relations Lead for Zoom
press@zoom.us

Investor Relations
Tom McCallum
Head of Investor Relations for Zoom
investors@zoom.us

INVNT GROUP Develops and Builds Three Immersive Brand Experiences

New York, NY, Sept. 30, 2021 (GLOBE NEWSWIRE) — [INVNT GROUP] and PepsiCo have strategically partnered to design and build three one-of-a-kind, interactive, and educational pavilions opening October 1^st , 2021. Each pavilion is designed around core sub-themes of Mobility, Sustainability, and Opportunity.

PepsiCo’s global brands including Aquafina®, Gatorade®, Pepsi® and Lay’s® headline the landmark pavilions; designed with the power of connectivity and sustainable futures in mind. 

Each pavilion has taken acute dedication, creativity, and labor – logging 6,032 hours for the Aquafina The Drop pavilion, 5,815 hours for the Gatorade The Bolt pavilion, and 5,943 hours for the Pepsi & Lay’s The Plus pavilion. Through advanced modular methodologies, INVNT GROUP in partnership with it’s on the ground fabrication partner in Dubai, Bespoke Modular Systems, has designed and engineered the pavilions with eco-conscious materials and considerations.

Scott Cullather, President & CEO, INVNT GROUP notes, “We’ve been working collaboratively with PepsiCo since 2006 on many of their largest activations and brand engagements across the portfolio. We are thrilled to continue that partnership through our purposeful work. The entire world will be present at this magnificent event, and we look forward to entertaining, educating, inspiring, and delighting.”

Jamal Wick, Managing Director, Bespoke Modular Systems added, “We are thrilled to support INVNT GROUP in bringing to life their designs for these iconic pavilions and can’t wait for the world to experience them firsthand this October.”

Aquafina: The Drop

The glistening Aquafina pavilion features 41,000 strategically placed recyclable aluminum cans on its exterior, creating a striking yet fluid water-drop structure. Visitors will be transported through The Drop pavilion as if within a water drop, while engaging with eye-opening statistics and ways to eradicate water inequity experienced by so many, globally.

It also delivers a high-tech experience with “Aquatar”: the 3D water encyclopedia that shares facts on the human body’s relationship to water. Aquatar was created with Unreal Engine, the world’s most open and advanced real-time 3D creation tool for cutting-edge content, interactive experiences, and immersive virtual worlds. Upon engaging, guests are transformed into water and water particles are displayed on a larger-than-life curved projection wall – all in real time.

Gatorade: The Bolt

Gatorade delves into to the science of physical performance and active lifestyles. The Bolt pavilion features multiple educational and shareable moments, starting with a retrospective of the Gatorade legacy and its relationship to some of the greatest athletes and sports moments of all time.

Visitors will get a look at the Gatorade Sports Science Institute (GSSI Lab), which boasts years of research focused on performance of the human body and its unending capabilities. Gatorade approaches personal hydration through innovation, with the GX™ Sweat Patch. Created to sync with your mobile device, the patch tracks performance vitals through perspiration, and offers bespoke recommendations for powering active lifestyles.

The Bolt pavilion also features an experiential moment where visitors can put their agility to the test against other visitors, through the Gatorade React Board.

Pepsi & Lay’s: The Plus

Bringing two of the world’s biggest brands under one roof, visitors can crunch and fizz through The Plus pavilion. Designed to engage all the senses through a kaleidoscope of bold flavors and rich colors, the pavilion creates a moment of joy and discovery.

Lay’s immersive pods allow visitors to bask in the renewing power of the spring season. Visitors can step into a striking cherry blossom display that is enhanced by scents of some of the most inventive Lay’s flavors from around the world.

Pepsi Black draws visitors into a multi-media world activated by cutting edge technology. Unity, the world’s leading platform for creating and operating interactive, real-time 3D (RT3D) content, powers interactive stations like the Pepsi Black “Pledge Wall” – a giant 5m x 4m LED curved wall where guests can enter a pledge and send their pledge into the fizzing world of Pepsi. The wall will hold all visitor’s pledges over the 6 months duration of the global conference. The number of pledges will keep accumulating and eventually the activation will cycle through thousands of pledges.

“PepsiCo will bring its unique sense of fun, ensuring that every guest makes the most of this iconic world gathering. The Bolt, The Drop, and The Plus are perfectly aligned with subthemes of Opportunity, Mobility and Sustainability and will showcase how PepsiCo will lead the world towards a fun and sustainable future,” said PepsiCo’s AMESA Chief Marketing Officer, Mustafa Shamseldin.

The pavilions will be open from 1 October 2021 through March 2022.

######

ABOUT INVNT GROUP

[INVNT GROUP] was established with a vision to provide consistent, meaningful, well-articulated BrandStory across all platforms. With offices in New York, Dubai, London, Singapore, San Francisco, Sydney, Stockholm, Detroit, and Washington D.C.; headed up by President and CEO, Scott Cullather, [INVNT GROUP], THE GLOBAL BRANDSTORY PROJECT™ represents a growing portfolio of complementary disciplines designed to help forward-thinking organizations everywhere, impact the audiences that matter, anywhere. The GROUP consists of modern brand strategy firm, Folk Hero; creative-led culture consultancy, Meaning; branded content studio and content marketing agency, HEVĒ; collegiate events and experiences, INVNT Higher Ed, and INVNT, the founding live brandstory telling agency. For more information about [INVNT GROUP], visit: www.invntgroup.com.

ABOUT PEPSICO

PepsiCo products are enjoyed by consumers more than one billion times a day in more than 200 countries and territories around the world. PepsiCo generated more than US$70 billion in net revenue in 2020, driven by a complementary food and beverage portfolio that includes Frito-Lay, Gatorade, Pepsi-Cola, Quaker, and Tropicana. PepsiCo’s product portfolio includes a wide range of enjoyable foods and beverages, including 23 brands that generate more than US$1 billion each in estimated annual retail sales.

Guiding PepsiCo is the vision to Be the Global Leader in Convenient Foods and Beverages by Winning with Purpose. “Winning with Purpose” reflects our ambition to win sustainably in the marketplace and embed purpose into all aspects of the business.  For more information, visit www.pepsico.com.

ABOUT BESPOKE MODULAR SOLUTIONS

Bespoke Modular Solutions (BMS) provides a new level of modular and prefabricated turnkey solutions to innovational real estate developers, hoteliers, and private residential projects to name a few. We offer a complete end-to-end solution, from a team of international experts that understand the region’s cultural and geographical sensitivities. Our designers and engineers have worked for the most renowned European companies in modular construction and in hotel operations.

Our company values live by building a better future for our next generation and children. We therefore are proud to say that we are pioneers in the region in off-site construction in an eco- friendly environment, with sustainable materials and in a time reduced manner. For more information, visit: www.bespoke-modular-solutions.com.

Attachment

• PepsiCo Pavilions

Jhonathan Mendez de Leon
[INVNT GROUP]®
3478192089
jmendezdeleon@invnt.com

New data from Sphera reveals that, despite promises to the contrary, companies struggle with implementing and disclosing progress on their sustainability efforts

CHICAGO, Sept. 30, 2021 (GLOBE NEWSWIRE) — Though pressure is growing from all corners—from investors, to governments, to boards of directors—companies worldwide struggle to report progress on their Environmental, Social and Governance (ESG) goals. Indeed, just 38% of businesses publicly communicate their sustainability performance, according to a new survey from Sphera^®, a leading global provider of ESG performance and risk management software, data and consulting services.

It’s not just a matter of disclosing progress on their objectives, however; companies are also behind the curve when it comes to clearly setting their ESG goals in the first place. Less than one-third (29%) of the respondents said they have set and communicated their sustainability targets, and even fewer—16%—have set emissions targets in accordance with the Science Based Targets initiative (SBTi) framework.

This marked lack of ESG transparency highlights the persistently wide chasm between ESG promises and action in the private sector. In the absence of significant, enforceable regulations worldwide, companies have largely been left to voluntarily make commitments, but with no meaningful mechanisms to either measure their progress or hold themselves accountable to them. About half (51%) of companies surveyed affirm that their senior management has made sustainability commitments, but only 21% say they have a clear roadmap to implementation, and just 26% say they have fully integrated sustainability into their business strategy.

“It’s easy to ‘talk the talk’ when it comes to corporate ESG initiatives, but much harder to ‘walk the walk’,” says Paul Marushka, Sphera’s CEO. “Businesses have largely been left to their own devices to establish and measure their sustainability performance, leading to a constellation of voluntary frameworks that ultimately disincentivize meaningful action. But with the Intergovernmental Panel on Climate Change’s recent report providing its strongest warning yet – indicating that half-measures will no longer cut it – and the upcoming COP26 conference promising to hold the business community to account, organizations need to start making good on their promises and show tangible progress.”

These findings are from Sphera’s Sustainability Survey 2021, a survey of 218 global business leaders evaluating their sustainability metrics, measurement and progress.

Additional findings from the survey include:

Scope 3 is missing from the menu. Though reducing emissions across the value chain is essential to meeting decarbonization targets and—for those businesses who have committed to them—achieving net zero emissions, very few companies have accounted for Scope 3 emissions in their sustainability plans. Only 13% of businesses surveyed said they have identified all relevant Scope 3 categories and completed a corresponding hotspot analysis; 29% say they consider the entire value chain when calculating their corporate emissions baseline or carbon footprint.

“Scope 3 emissions can make up the vast majority of a company’s overall carbon footprint,” Marushka added, “which means any sound sustainability strategy must involve an assessment of the supply chain and a commitment to working with suppliers who are also taking measurable steps to reduce their emissions. The end result ultimately creates a multiplier effect for both companies’ sustainability efforts.”

Poor data quality can stymie even the best efforts. Only a minority of respondents (16%) use data from established commercial databases to quantify their corporate carbon footprint; another 14% say they use high-quality, industry-based data for baseline assessment at the product level. In practice, this means many more organizations are using suboptimal datasets, such as spend-based, input-output databases, to measure their emissions. These types of top-down, nonspecific data sources can lead to inaccurate assessments, further exacerbating the gap between sustainability promises and outcomes.

The middle market struggles the most. Perhaps unsurprisingly, large organizations with more than $1 billion in revenue are more likely to be rated as optimized (34%) in terms of sustainability maturity.¹ At the same time, 39% of small businesses with less than $100 million in revenue are considered optimized. Midsize businesses trail both, with an optimization rate of just 30%. In fact, midsize businesses are more likely than their larger or smaller counterparts to not exceed basic compliance requirements (25% vs.13% for smaller organizations and 6% for larger organizations).

About the Sustainability Maturity Survey 2021
Sphera partnered with the University of Esslingen in Germany to design and field a survey of companies throughout Europe, North America and Asia-Pacific. Respondents represented businesses in a wide range of industries, including automotive, construction, education, health care, oil and gas, manufacturing and technology. The survey was conducted between April 7 and May 3.

About Sphera
Sphera creates a safer, more sustainable and productive world. We are a leading global provider of Environmental, Social and Governance (ESG) performance and risk management software, data and consulting services with a focus on Environment, Health, Safety & Sustainability (EHS&S), Operational Risk Management and Product Stewardship.

Press Contact
Kylie Souder
kylie.souder@aspectusgroup.com
+1 513-304-5776

__________________
¹ According to Sphera’s Sustainability Maturity rubric, an “optimized” business leverages ESG software and data resources to go above and beyond meeting compliance requirements to help find efficiencies, increase productivity and innovation, reduce costs and mitigate risks. A “leader” is at the head of the competitive pack and is shaping the future of its sector through its sustainability initiatives.

ADG20 Continues to be Well Tolerated in Healthy Volunteers with Prolonged Half-Life and Serum Virus Neutralization Activity Observed out to Six Months in Ongoing Phase 1 Study

Data from Quantitative Systems Pharmacology/Whole-Body Physiologically Based Pharmacokinetic Modeling Support Evaluation of 300 mg Intramuscular Dose of ADG20 Given as a Single Intramuscular Injection in Ongoing Phase 2/3 Studies

Data to be Presented During IDWeek 2021 and 19^th Annual Discovery on Target Conference

WALTHAM, Mass., Sept. 29, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced new data from the company’s COVID-19 antibody program. Updated, six-month data from its ongoing Phase 1 study of ADG20 in healthy participants and data validating the selection of the 300 mg intramuscular (IM) dose given as a single injection that is being evaluated in the company’s ongoing global Phase 2/3 treatment (STAMP) and prevention (EVADE) clinical trials will be presented during four poster sessions at the Infectious Disease Society of America’s IDWeek 2021, being held from Sept. 29 – Oct. 3, 2021. In addition, Adagio’s chief scientific officer, Laura Walker, Ph.D., will present a subset of the ADG20 Phase 1 data as well as background on the identification and optimization of this differentiated antibody clinical candidate in an oral presentation at the 19^th Annual Discovery on Target Conference on Sept. 30, 2021.

“The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 – which was designed to be potent, broadly neutralizing and delivered as a single IM injection – could have on people with or at risk of COVID-19,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “These Phase 1 data combined with our dose selection strategy, which relied on our innovative modeling approach, have allowed us to initiate and advance our pivotal trials of ADG20 in the treatment and prevention of COVID-19. We anticipate these data will support an Emergency Use Authorization (EUA) application in the first quarter of 2022, which could enable us to bring an important treatment option to patients.”

Phase 1 Trial Update
Adagio is evaluating ADG20 in a Phase 1 randomized, double-blind, placebo-controlled single ascending-dose study to assess safety and tolerability, pharmacokinetics (PK), immunogenicity, and serum virus neutralizing activity of ADG20 ex vivo against SARS-CoV-2. Data from a six-month evaluation timepoint confirmed the extended half-life of ADG20, which approached 100 days based on data from the 300 mg IM dose that was given as a single injection. In addition, 50% serum virus neutralization titers at six months after a 300 mg IM dose of ADG20 were similar to observed peak titers with the mRNA-1273 vaccine and exceeded those achieved with the AZD1222 vaccine series. Importantly, ADG20 was well tolerated with no study drug-related adverse events (AEs), serious AEs, or injection-site or hypersensitivity reactions reported through a minimum of three months follow-up across all cohorts. Participants will continue to be followed through 12 months to assess safety and tolerability, PK, immunogenicity and serum virus neutralizing activity.

Phase 1 Poster Information: (633) Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Dose Selection Strategy
To support dose selection for Adagio’s global Phase 2/3 STAMP and EVADE clinical trials, the company modified an existing quantitative systems pharmacology whole-body physiologically-based pharmacokinetic (QSP/PBPK) model to better characterize the PK of extended half-life monoclonal antibodies in serum and key sites of viral replication in the respiratory tract. Adagio’s model adequately a priori predicted the observed ADG20 serum PK in non-human primates (NHPs) and humans. The model was further optimized based on data from Adagio’s Phase 1 clinical trial and then applied for dose selection for STAMP and EVADE.

For the STAMP treatment trial, data compiled to date suggest that the 300 mg IM regimen has a projected ability to rapidly achieve and maintain target concentrations at key tissue sites of viral replication, including the ability to attain near complete (> 90%) and durable (> 28-day) SARS-CoV-2 receptor occupancy across a range of baseline viral loads. Further, for the EVADE prevention trial, data compiled to date suggest the 300 mg IM regimen has a projected ability to rapidly exceed target serum concentrations in the majority of simulated patients and to maintain potentially effective concentrations for up to 12 months.

Dose Selection Poster Information

• (1086) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model that a priori Predicts Intramuscular (IM) Pharmacokinetics of ADG20: an Extended Half-life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
• (1089) Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)
• (1088) A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

The STAMP and EVADE clinical trials are currently ongoing and enrolling patients globally. For more information, please visit clincialtrials.gov.

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is administered by a single intramuscular injection, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers to support the completion of clinical trials and initial commercial launch. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of ADG20, including the timing of our planned EUA application, initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs; our ability to obtain and maintain regulatory approvals for, our product candidates; our ability to identify patients with the diseases treated by our product candidates and to enroll these patients in our clinical trials; our manufacturing capabilities and strategy; and our ability to successfully commercialize our product candidates. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, those risks described under the heading “Risk Factors” in Adagio’s prospectus filed with the Securities and Exchange Commission (“SEC”) on August 6, 2021 and in Adagio’s future reports to be filed with the SEC, including Adagio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2021. Such risks may be amplified by the impacts of the COVID-19 pandemic. Forward-looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com